Abstract
Although many population pharmacokinetics (PPK) researches have been conducted on chemical drugs, few have been in the field of Chinese medicine (CM). Each ingredient in CMs possesses different pharmacokinetic characteristics, therefore, it is important to develop methods of PPK studies on them to identify the differences in CM drug safety and efficacy among the population subgroups and to conduct quantitative studies on the determinants of CM drug concentrations. To develop an expert consensus on study design and implementation for PPK of CM, in August 2013, 6 experts in the field of PPK, CMs pharmacology, and statistics discussed problems on the PPK research protocol of CMs, and a consensus was reached. The medicines with toxicity and narrow therapeutic windows and with wide range of target population or with frequent adverse reactions were selected. The compositions with definite therapeutic effects were selected as indices, and specific time points and sample sizes were designed according to standard PPK design methods. Target components were tested through various chromatography methods. Total quantity statistical moment analysis was used to estimate PPK parameters of each component and PPK models reflecting the trend of CMs (which assists in reasonable adjustments on clinical dosage). This consensus specifies the study design and implementation process of PPK. It provides guidance for the following: post-marketing clinical studies, in vivo investigations related to the metabolism in different populations, and development and clinical adjustment of dosages of CMs.
Similar content being viewed by others
References
The Food and Drug Administration. Guidance for industry. Population pharmacokinetics. 1999. Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM072137.pdf
Technical Guidance Study Group. Technical guidance for pharmacokinetics of chemical drugs code. 2005. Available from: http://www.acec.gov.cn/info/info/2009224834320.pdf
Peng L, Gao XY, Guo MX, Su JK. Researching ideas of traditional Chinese medicine pharmacokinetics. The fifth academic conference proceedings of Specialty Committee of Analysis of Chinese Medicine. China Assoc Chin Med (Chin) 2012;209–212.
Zhao YN, Xing DM, Ding Y, Pan WS, Wang W, Cheng J, et al. Pharmacokinetic study on the antipyretic compound YL2000. Chin Pharmacol Bullet (Chin) 2004;20:776–780.
Liu HF, Yang JL, Du FF, Gao XM, Ma XT, Huang YH, et al. Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab Dispos 2009;37:2290–2298.
The Food and Drug Administration. Guidance for industry bioanalytical method validation. 2001. Available from: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf.
He FY, Deng KW, Liu WL, Shi JL, Yang YT. Population pharmacokinetics of multiple-ingredient system of compound chinese medicines: mathematic model for total quantum statistical moment and parameter calculation study. China J Chin Mater Med (Chin) 2011;36:2866–2870.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by the Significant Drug Research and Development in Important State Science and Technology Specific and Key Technique Research (No. 2009ZX09502-030), Visiting Fellow Joint Innovation Research Project of the China Academy of Chinese Medicial Sciences (No. ZZ070834), and the Specialty Committee of Evaluation of Postmarketing Chinese Medicines of World Federation of Chinese Medicine Societies
Rights and permissions
About this article
Cite this article
Jiang, Jj., Zhang, W., Xie, Ym. et al. Study design and implementation for population pharmacokinetics of Chinese medicine: An expert consensus. Chin. J. Integr. Med. 22, 154–160 (2016). https://doi.org/10.1007/s11655-014-1995-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-014-1995-z